|
2004 Arthritis
Advisory Committee Meeting on Gout Date and Time: June 2 and 3, 2004, from 8
a.m. to 5 p.m.
Location: Food and Drug Administration, Center for Drug
Evaluation and
Research Advisory Committee Conference Room, 5630 Fishers Lane,
rm. 1066,
Rockville, MD.
Agenda:
On June 2, 2004, the committee will
discuss trial design and
endpoints for drugs for chronic gout, including new drug
application (NDA)
21-740, oxypurinol (proposed tradename, Oxiprim), Cardiome.
On June 3, 2004, the committee will
discuss trial design and endpoints for drugs for acute
gout, including NDA 21-389, etoricoxib (proposed tradename,
Arcoxia),
Merck.
Federal
Register Notice for Meeting
Contact Person:
Kimberly Littleton Topper, Center for Drug
Evaluation and Research (HFD-21), Food and Drug Administration, 301-827-7001, Fax: 301-827-6801, email:
topperk@cder.fda.gov
Please call the Information Line for up-to-date
information on this meeting,
1-800-741-8138 (301-443-0572 in the Washington, DC area), code
3014512532.
Back
to Top
Analgesia and Anti-inflammatory Drugs
Date created: April 29, 2004 |
|